BR112017008097A2 - método para tratar condições oculares - Google Patents

método para tratar condições oculares

Info

Publication number
BR112017008097A2
BR112017008097A2 BR112017008097-4A BR112017008097A BR112017008097A2 BR 112017008097 A2 BR112017008097 A2 BR 112017008097A2 BR 112017008097 A BR112017008097 A BR 112017008097A BR 112017008097 A2 BR112017008097 A2 BR 112017008097A2
Authority
BR
Brazil
Prior art keywords
eye conditions
treating eye
treating
conditions
methods
Prior art date
Application number
BR112017008097-4A
Other languages
English (en)
Other versions
BR112017008097B1 (pt
Inventor
Ackermann
Michael Douglas
Jr.
Loudin
James
Mandell
J. Kenneth
Original Assignee
Oyster Point Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017008097(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oyster Point Pharma, Inc. filed Critical Oyster Point Pharma, Inc.
Priority to BR122022025737-2A priority Critical patent/BR122022025737B1/pt
Publication of BR112017008097A2 publication Critical patent/BR112017008097A2/pt
Publication of BR112017008097B1 publication Critical patent/BR112017008097B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)

Abstract

no presente documento são descritos métodos e formulações farmacêuticas para tratar condições oculares.
BR112017008097-4A 2014-10-20 2015-10-19 Método para tratar condições oculares BR112017008097B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122022025737-2A BR122022025737B1 (pt) 2014-10-20 2015-10-19 Método para tratar condições oculares

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462066280P 2014-10-20 2014-10-20
US62/066,280 2014-10-20
US201562100844P 2015-01-07 2015-01-07
US62/100,844 2015-01-07
PCT/US2015/056273 WO2016064759A1 (en) 2014-10-20 2015-10-19 Methods of treating ocular conditions

Publications (2)

Publication Number Publication Date
BR112017008097A2 true BR112017008097A2 (pt) 2018-02-20
BR112017008097B1 BR112017008097B1 (pt) 2023-03-28

Family

ID=55748136

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122022025737-2A BR122022025737B1 (pt) 2014-10-20 2015-10-19 Método para tratar condições oculares
BR112017008097-4A BR112017008097B1 (pt) 2014-10-20 2015-10-19 Método para tratar condições oculares

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122022025737-2A BR122022025737B1 (pt) 2014-10-20 2015-10-19 Método para tratar condições oculares

Country Status (20)

Country Link
US (11) US9504644B2 (pt)
EP (3) EP3848028B1 (pt)
JP (3) JP6873906B2 (pt)
KR (2) KR102601505B1 (pt)
CN (3) CN107106542B (pt)
AU (2) AU2015336216B2 (pt)
BR (2) BR122022025737B1 (pt)
CA (1) CA2965129C (pt)
DK (2) DK3209295T4 (pt)
EA (1) EA035335B1 (pt)
ES (1) ES2848977T5 (pt)
FI (1) FI3848028T3 (pt)
IL (2) IL251769B (pt)
MX (2) MX2017005064A (pt)
MY (1) MY186870A (pt)
PH (1) PH12017500602A1 (pt)
PT (1) PT3209295T (pt)
SG (2) SG10202011669PA (pt)
WO (1) WO2016064759A1 (pt)
ZA (1) ZA201703467B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015336216B2 (en) 2014-10-20 2020-05-21 Oyster Point Pharma, Inc. Methods of treating ocular conditions
CA3020170A1 (en) * 2016-04-07 2017-10-12 Oyster Point Pharma, Inc. Methods of treating ocular conditions
WO2020014232A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
CA2468705A1 (en) 2001-11-29 2003-06-05 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
CA2586074C (en) * 2004-11-09 2013-07-23 Novagali Pharma Sa Ophthalmic oil-in-water type emulsion with stable positive zeta potential
AU2006226509A1 (en) * 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
WO2007025286A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
EP1933852B1 (en) 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
TWI405763B (zh) 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
EP2114970B1 (en) * 2007-02-02 2011-08-03 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20090215787A1 (en) 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
EP2257549A1 (en) 2008-03-05 2010-12-08 Targacept Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
US20110263629A1 (en) * 2008-09-05 2011-10-27 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
SG10201902903RA (en) 2008-12-01 2019-05-30 Oyster Point Pharma Inc Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
US20140170157A1 (en) * 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
US20140128606A1 (en) * 2011-06-30 2014-05-08 Toray Industries, Inc. Antipruritic agent
JO3766B1 (ar) * 2011-10-20 2021-01-31 Novartis Ag منشط مستقبل أسيتيل كولين الفا - 7 النيكوتيني
US20140357971A1 (en) * 2011-11-30 2014-12-04 Diagnostear Ltd. Dry eye diagnostic
ES2426517B1 (es) * 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
ES2649730T3 (es) 2013-03-15 2018-01-15 Glia Llc Distribución craneal de compuestos farmacéuticos
CN105307718B (zh) 2013-04-19 2018-05-11 奥库利维公司 鼻刺激装置和方法
AU2015336216B2 (en) 2014-10-20 2020-05-21 Oyster Point Pharma, Inc. Methods of treating ocular conditions
CA3020170A1 (en) 2016-04-07 2017-10-12 Oyster Point Pharma, Inc. Methods of treating ocular conditions
WO2020014232A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions

Also Published As

Publication number Publication date
US20160106665A1 (en) 2016-04-21
CN107106542A (zh) 2017-08-29
IL251769A0 (en) 2017-06-29
JP7502404B2 (ja) 2024-06-18
US20230226054A1 (en) 2023-07-20
US11224598B2 (en) 2022-01-18
MX2017005064A (es) 2018-02-23
US20170239244A1 (en) 2017-08-24
KR102601505B1 (ko) 2023-11-14
DK3209295T3 (da) 2021-03-01
CA2965129C (en) 2024-03-12
SG11201703135XA (en) 2017-05-30
US9597284B2 (en) 2017-03-21
ES2848977T3 (es) 2021-08-13
IL293188A (en) 2022-07-01
US20230226053A1 (en) 2023-07-20
US20200246336A1 (en) 2020-08-06
PH12017500602A1 (en) 2017-09-04
US20240173318A1 (en) 2024-05-30
BR112017008097B1 (pt) 2023-03-28
CN111956650B (zh) 2024-06-04
US20160106746A1 (en) 2016-04-21
US20220233528A1 (en) 2022-07-28
US11903943B2 (en) 2024-02-20
EP3209295A4 (en) 2018-05-23
AU2015336216B2 (en) 2020-05-21
US11911380B2 (en) 2024-02-27
US9504644B2 (en) 2016-11-29
MY186870A (en) 2021-08-26
KR102511955B1 (ko) 2023-03-22
EP3209295B1 (en) 2020-12-09
US9532944B2 (en) 2017-01-03
EP3848028B1 (en) 2024-05-29
EA035335B1 (ru) 2020-05-28
US20160106745A1 (en) 2016-04-21
US10456396B2 (en) 2019-10-29
EP3848028A1 (en) 2021-07-14
JP6873906B2 (ja) 2021-05-19
PT3209295T (pt) 2021-02-05
MX2022005888A (es) 2022-06-14
DK3848028T3 (da) 2024-08-26
FI3848028T3 (fi) 2024-08-21
DK3209295T4 (da) 2024-02-26
US20160106744A1 (en) 2016-04-21
EP3209295B2 (en) 2023-12-06
EP4413974A2 (en) 2024-08-14
ZA201703467B (en) 2023-12-20
EA201790893A1 (ru) 2018-01-31
CN111956650A (zh) 2020-11-20
IL251769B (en) 2022-06-01
AU2020213351A1 (en) 2020-08-27
AU2015336216A1 (en) 2017-06-08
ES2848977T5 (es) 2024-06-06
CN111956803A (zh) 2020-11-20
CA2965129A1 (en) 2016-04-28
KR20230042144A (ko) 2023-03-27
SG10202011669PA (en) 2020-12-30
WO2016064759A1 (en) 2016-04-28
JP2017531044A (ja) 2017-10-19
AU2020213351B2 (en) 2023-04-06
JP7257371B2 (ja) 2023-04-13
CN107106542B (zh) 2020-05-08
US11903941B2 (en) 2024-02-20
US9504645B2 (en) 2016-11-29
US11903942B2 (en) 2024-02-20
KR20170086040A (ko) 2017-07-25
EP3209295A1 (en) 2017-08-30
US20230226052A1 (en) 2023-07-20
JP2021038250A (ja) 2021-03-11
JP2023024574A (ja) 2023-02-16
BR122022025737B1 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
HK1232141A1 (zh) 用於治療亨廷頓病的方法和組合物
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
CO2017003311A2 (es) Sistema y método de reconocimiento de imágenes
BR112016026939A2 (pt) aparelho e método.
BR112016019071A2 (pt) método para preparar uma célula t engenheirada, célula t engenheirada, e seus usos
GB2541571A (en) Pharmaceutical compositions
DK3153169T3 (da) Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt
BR112016022222A2 (pt) aparelho, sistema e método para detonação
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
DK3157527T3 (da) Ezh2-hæmmere til lymfombehandling
EP3125757A4 (en) System and method for focal source identification
IL252475B1 (en) Method and devices for optical symmetrization of a pupil
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112016027102A2 (pt) método e aparelho
DK3393579T3 (da) Øjenbehandlingssystem
DK3094640T3 (da) Fremgangsmåder til steril kromatografi og fremstilling
ES2978694T3 (es) Sistema y método para generar gráficos de relaciones
EP3117210A4 (en) Compositions and methods for treating eye infections and disease
PH12017500602A1 (en) Methods for treating ocular conditions
DK3282008T3 (da) Sporulationsfremgangsmåde for Bacillus bacterium
EP3515263A4 (en) DEVICE FOR PUTTING ON SOCKS, AND METHOD FOR OPERATING SUCH A DEVICE
UY36286A (es) Tratamientos médicos basados en anamorelina
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: OYSTER POINT PHARMA, INC. (US)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022025737-2 PROTOCOLO 870220118266 EM 15/12/2022 22:33.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/10/2015, OBSERVADAS AS CONDICOES LEGAIS